# Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures

4

Kelly R. Barnett, PhD<sup>1,2</sup>, Robert J. Mobley, PhD<sup>1,2</sup>, Jonathan D. Diedrich, PhD<sup>1,2</sup>, Brennan P. Bergeron,
PhD<sup>1,2,3</sup>, Kashi Raj Bhattarai, PhD<sup>1,2</sup>, Wenjian Yang, PhD<sup>1,2</sup>, Kristine R. Crews, PharmD<sup>1,2</sup>, Christopher
S. Manring, MBA<sup>4</sup>, Elias Jabbour, MD<sup>5</sup>, Elisabeth Paietta, PhD<sup>6</sup>, Mark R. Litzow, MD<sup>7</sup>, Steven M.
Kornblau, MD<sup>5</sup>, Wendy Stock, MD<sup>8</sup>, Hiroto Inaba, MD, PhD<sup>1,9</sup>, Sima Jeha, MD<sup>1,9</sup>, Ching-Hon Pui, MD<sup>1,9</sup>,

9 Charles G. Mullighan, MBBS (Hons), MSc, MD<sup>1,10</sup>, Mary V. Relling, PharmD<sup>1,2</sup>, Jun J. Yang, PhD<sup>1,2,3,11</sup>,
10 William E. Evans, PharmD<sup>1,2</sup> and Daniel Savic, PhD<sup>1,2,3,11,\*</sup>

- 11
- 12
- 13

<sup>1</sup>Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

<sup>2</sup> Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
 38105, USA.

<sup>3</sup> Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

<sup>4</sup>Alliance Hematologic Malignancy Biorepository; Clara D. Bloomfield Center for Leukemia Outcomes Research,

19 Columbus, OH 43210, USA

<sup>5</sup> Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

<sup>6</sup> Department of Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.

<sup>7</sup> Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.

<sup>8</sup> University of Chicago Comprehensive Cancer Center, Chicago, IL 60637, USA.

<sup>9</sup> Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

<sup>10</sup> Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

<sup>11</sup> Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, TN

27 38105, USA.

\*Corresponding author:
Daniel Savic, PhD
Division of Pharmaceutical Sciences
Department of Pharmacy and Pharmaceutical Sciences
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN, 38105
daniel.savic@stjude.org

Key words: Acute lymphoblastic leukemia, ATAC-seq, chromatin accessibility, gene regulation, gene
 regulatory network, transcription factor, transcription factor footprints, genetic variation, ATAC-QTLs

## 39 SUMMARY

B-cell lineage acute lymphoblastic leukemia (B-ALL) is comprised of diverse molecular subtypes and 40 41 while transcriptional and DNA methylation profiling of B-ALL subtypes has been extensively examined. 42 the accompanying chromatin landscape is not well characterized for many subtypes. We therefore 43 mapped chromatin accessibility using ATAC-seq for 10 B-ALL molecular subtypes in primary ALL cells 44 from 154 patients. Comparisons with B-cell progenitors identified candidate B-ALL cell-of-origin and 45 AP-1-associated cis-regulatory rewiring in B-ALL. Cis-regulatory rewiring promoted B-ALL-specific gene regulatory networks impacting oncogenic signaling pathways that perturb normal B-cell development. 46 47 We also identified that over 20% of B-ALL accessible chromatin sites exhibit strong subtype enrichment, with transcription factor (TF) footprint profiling identifying candidate TFs that maintain 48 49 subtype-specific chromatin architectures. Over 9000 inherited genetic variants were further uncovered 50 that contribute to variability in chromatin accessibility among individual patient samples. Overall, our 51 data suggest that distinct chromatin architectures are driven by diverse TFs and inherited genetic 52 variants which promote unique gene regulatory networks that contribute to transcriptional differences 53 among B-ALL subtypes. 54 55 56 57 58 59 60 61 62 HIGHLIGHTS 63 Pro-B progenitor cells as the most common cell-of-origin for B-ALL 64 65 AP-1 TF-associated *cis*-regulatory rewiring in B-ALL • 66 Subtype-specific accessible chromatin signatures representing 20% of all B-ALL sites • Role for distinct TFs in promoting subtype-specific chromatin architectures 67 • 68 Thousands of inherited genetic variants identified impacting chromatin state • 69 70 71

## 72 INTRODUCTION

73 Acute lymphoblastic leukemia (ALL) is derived from B- and T-cell lineage precursor cells and is the 74 most common childhood cancer<sup>1</sup>. A majority of acute lymphoblastic leukemias are derived from B-cell 75 lineages (B-ALL) that are comprised of distinct molecular subtypes characterized by unique 76 chromosomal lesions, including an euploidy, translocations, gene fusions, point mutations and other chromosomal rearrangements that drive leukemogenesis<sup>2</sup>. Numerous studies have identified extensive 77 heterogeneity in transcriptomes <sup>3,4</sup> and DNA methylomes <sup>5,6</sup> among B-ALL subtypes in large patient 78 79 cohorts, but there is limited understanding of chromatin landscapes. Here we provide an extensive 80 survey of accessible chromatin state and *cis*-regulatory element activity in primary B-ALL cells from 81 over 150 patients across the United States.

82 Chromatin accessibility or open chromatin is a hallmark of active *cis*-regulatory elements that control spatial and temporal gene expression <sup>7</sup>. Because ALL typically involves mutations (PAX5-83 84 altered), complex rearrangements (DUX4-rearranged, PAX5-altered, ZNF384-rearranged, etc.) and/or oncogenic gene fusions (ETV6::RUNX1, TCF3::PBX1, KMT2A-rearranged, etc.) of transcription factor 85 86 (TF) genes as well as disruptions of *cis*-regulatory elements<sup>8</sup>, chromatin accessibility maps can provide 87 valuable information to better understand the leukemogenic process. Accessible chromatin sites can be mapped using transposases by performing assay for transposase-accessible chromatin with high-88 throughput sequencing (ATAC-seq)<sup>9,10</sup>. Although DNase treatment has also been used <sup>11</sup>, one key 89 advantage of ATAC-seg is the low sample input requirements compared to DNase-based assays. This 90 91 makes ATAC-seg an attractive assay for mapping open chromatin in primary cells from patients 92 wherein sample availability is limited. Additionally, chromatin accessibility allows for identification of bound TFs through an examination of TF footprints which are defined by a depletion in DNA 93 transposition <sup>12</sup> or DNase <sup>13</sup> cleavage events within regions of accessible chromatin signal. As a result, 94 the underlying TF-binding gene regulatory networks that promote chromatin accessibility and 95 96 differential gene expression can be predicted.

97 Previous large-scale studies of chromatin accessibility in primary cells have predominantly focused on distinct cell types <sup>10,14</sup> or distinct tumor types and locations <sup>15,16</sup>. Therefore, large-scale 98 99 analyses aimed to better understand chromatin state in a single heterogeneous malignancy are 100 currently lacking. To address this knowledge gap, we mapped chromatin accessibility in fresh primary ALL cells from 154 patients across 10 molecular subtypes of B-ALL (BCR::ABL1, DUX4-rearranged, 101 102 ETV6::RUNX1, high hyperdiploid, low hypodiploid, KMT2A-rearranged, BCR::ABL1-like (Ph-like), 103 PAX5-altered, TCF3::PBX1, ZNF384-rearranged) and B-other patient samples. Notably, these 104 subtypes span the entire spectrum of clinical prognoses, including patients with excellent (DUX4-105 rearranged, ETV6::RUNX1, high hyperdiploid), good (TCF3::PBX1), intermediate (ZNF384-rearranged,

PAX5-altered) and poor (*BCR::ABL1*, low hypodiploid, *KMT2A*-rearranged and Ph-like) prognosis. We
 also mapped histone H3 lysine 27 acetylation (H3K27ac) enrichment using ChIP-seq in a subset of
 these patient samples to additionally infer functional activity.

109 Using ATAC-seg chromatin accessibility and histone profiling in primary ALL cells, we mapped 110 cis-regulatory element activity in B-ALL. In complement to chromatin accessibility profiling, we identified 111 thousands of chromatin loops targeting promoters in multiple B-ALL cell lines to better inform linkages 112 of *cis*-regulatory elements to cognate genes. We coupled these maps to transcription factor (TF) 113 footprints at accessible chromatin sites to identify key TFs and gene regulatory networks across B-ALL 114 samples and within distinct B-ALL subtypes. Our results identified extensive chromatin reprogramming 115 between B-cell progenitors and B-ALL, as well as extensive heterogeneity in accessible chromatin 116 landscapes among B-ALL subtypes. Specifically, we uncovered a focused subset of over 42,000 B-ALL 117 open chromatin sites exhibiting extensive subtype-enrichment and subtype-enriched TF binding events. 118 Notably, these sites can predict and classify B-ALL samples with 86% cross-validation accuracy. We 119 additionally explored the impact of inherited genetic variation on chromatin state and delineated over 120 9000 ATAC-seq chromatin accessibility quantitative trait loci (ATAC-QTLs) in B-ALL cells, including a 121 subset that alter neighboring gene expression. Using the largest accessible chromatin accessibility 122 dataset for B-ALL to date, our data collectively support substantial subtype-specificity in chromatin 123 accessibility that is driven in part by distinct TFs, as well as pronounced inter-individual heterogeneity in 124 chromatin state through inherited genetic variants. Our work further supports the role of these distinct 125 chromatin architectures in establishing unique gene regulatory networks that impact gene expression 126 and B-ALL cell biology.

- 127
- 128
- 129

#### 130 **RESULTS**

#### 131 Chromatin accessibility profiles of B-ALL patient samples spanning multiple subtypes

ATAC-seq using the Fast-ATAC <sup>10</sup> method was performed on recently-harvested primary ALL cells from 133 154 patients spanning 10 B-ALL molecular subtypes (*BCR::ABL1*, *DUX4*-rearranged, *ETV6::RUNX1*, 134 high hyperdiploid, low hypodiploid, *KMT2A*-rearranged, Ph-like, *PAX5*-altered, *TCF3::PBX1*, *ZNF384*-135 rearranged) and B-other samples (**Table S1**) from diverse medical centers, research groups and 136 clinical trials networks across the United States (see **Methods**). To identify high-confidence sites, we 137 identified ATAC-seq peak summits using subtype merged data and selected only loci reproducible 138 among unmerged individual patients. Using this approach we identified 110,468 accessible chromatin

139 fsites, on average, in each B-ALL subtype (range= 71.797–142.498), with 217.240 merged sites 140 identified in total representing the final genomic regions of interest (Figure 1A, Table S2). 141 Using H3K27ac ChIP-seg data generated from a subset of 11 B-ALL patient samples, as well as 142 primary B-ALL cell H3K27ac, H3K4me1 and H3K27me3 ChIP-seq data from the Blueprint Epigenome 143 Consortium (https://www.blueprint-epigenome.eu/), we determined that nearly all open chromatin sites 144 mapped to regions containing only active histone marks (H3K27ac and/or H3K4me1, 89.6%; 145 H3K27ac= 3.3%, H3K4me1=34% and H3K4me1+H3K27ac=52.3%) or regions with bivalent marks 146 suggesting a poised chromatin state (H3K27ac and/or H3K4me1 and H3K27me3, 8.9%), compared to 147 only 1.5% of ATAC-seq sites that mapped to regions solely harboring repressive chromatin 148 (H3K27me3; Figure 1B). Because these histone modifications are typically found at transcriptional enhancers and promoters<sup>17-20</sup>, these findings suggest that these accessible chromatin regions are B-149 150 ALL cis-regulatory elements implicated in gene regulation.

151 In most cases, these candidate *cis*-regulatory elements map within intergenic or intragenic loci 152 with unclear gene targets. Therefore, to better inform gene connectivity we produced chromatin looping data using promoter capture Hi-C<sup>21</sup> across seven B-ALL cell lines (697, BALL1, Nalm6, REH, RS411, 153 154 SEM and SUPB15) to complement B-ALL patient chromatin accessibility profiles. Collectively, across 155 the B-ALL cell lines we detected approximately 400,000 chromatin loops, with approximately 50% of 156 the 217,240 chromatin accessible regions of interest intersecting with a promoter loop, including 15,929 chromatin accessible sites that looped to a cancer implicated gene set (Figure 1C)<sup>22,23</sup>. In many 157 158 instances, large domains of extensive chromatin looping are present, which with chromatin accessibility 159 and active histone marks emphasize the gene regulatory networks present across B-ALL patient 160 samples (e.g., Figures 1D and 1E).

161

#### 162 Chromatin accessibility identifies Pro-B cell-of-origin for most B-ALL patient samples

163 To better understand chromatin remodeling during leukemogenesis we sought a comparison of 164 chromatin accessibility between B-ALL and B-cell progenitors. Moreover, although it is widely accepted 165 that the B-ALL cell-of-origin is a B-cell precursor, exactly which precursor is not always clear, particularly at the chromatin accessibility level <sup>24</sup>. To resolve this uncertainty, we examined publicly 166 available ATAC-seq data from several human B-cell progenitors<sup>10,25</sup> (Figure 2A). When comparing 167 168 chromatin accessibility signal between B-cell progenitor groups, we identified a set of approximately 169 42,344 genomic loci which demonstrate a chromatin accessibility enrichment or depletion trend for a B-170 cell progenitor (Figure 2B, Table S3). We refer to these chromatin loci as B-progenitor identity loci due 171 their distinct patterning across B-progenitor differentiation and are likely representations of stage-172 specific gene regulatory programs.

173 Next, we examined patient B-ALL cell chromatin accessibility across these B-progenitor identity 174 loci. When plotting chromatin accessibility signal as a heatmap comparing B-cell progenitors and B-ALL 175 patient samples, a high degree of similarity was observed with prePro-B cells and Pro-B cells (Figure 176 **2B**). Further, when applying the K-nearest neighbor classification model previously trained on B-177 progenitor identity loci the majority of B-ALL samples classified as either prePro-B or Pro-B (Figures 178 2C and 2D). However, prePro-B cells have been reported to be an extremely rare population beyond 179 embryonic and fetal development<sup>25</sup>. Overall, Pro-B cells demonstrate the most similarity to B-ALL cells 180 at the chromatin accessibility level when focusing specifically on B-cell precursor defining loci, 181 emphasizing this precursor B-cell as a common cell-of-origin for B-ALL.

182

#### 183 Extensive differences in chromatin accessibility between B-ALL and Pro-B cells

184 To better understand chromatin remodeling during leukemogenesis we next compared accessible 185 chromatin sites between B-ALL and Pro-B cells (n=3) and uncovered 42,661 differentially accessible 186 chromatin sites (DAS) exhibiting lesser or greater accessibility in B-ALL samples (Figures 3A and 3B; 187 Figure S1 and Table S4). Ontology analysis focusing strictly on DAS with higher chromatin 188 accessibility in B-ALL indicated an enrichment for sites associated with genes involved with toll-like 189 receptor signaling, interleukin production, metabolism (acetyl-CoA production) and cell proliferation 190 (Figure 3C). Enriched ontology terms were frequently present at multiple fold change thresholds of 191 input B-ALL DAS (Table S5).

192 In addition to profiling differential chromatin accessibility, global transcription factor (TF) binding 193 was also compared between B-ALL and Pro-B cells. To identify differential TF binding, we performed 194 genome-wide TF footprint profiling <sup>12</sup> using 810 TF motifs comparing B-ALL patient samples and normal 195 Pro-B cell samples across all B-ALL genomic regions of interest (217,240 regions). Differential binding 196 scores indicated the AP-1 family of TFs (e.g., FOS, JUN) as the most prominent TFs with higher 197 binding in B-ALL patient samples compared to normal Pro-B cells (Figure 3D). In contrast, prominent 198 TFs with higher binding in Pro-B cells were TFs such as TFAP2A, KLF15, CTCFL, ZBTB14 and EBF1. 199 To further demonstrate AP-1 TF occupancy in B-ALL accessible chromatin sites we performed 200 CUT&RUN for FOSL2. JUN and JUNB in 697 and SUB15 human B-ALL cell lines (Figure 3E: Figure 201 S2). Intersections with B-ALL accessible chromatin sites from primary cells identified that 27% of these 202 sites were occupied by an AP-1 TF in B-ALL cell lines. Strikingly, our results further uncovered that 203 45% of DAS with higher chromatin accessibility in B-ALL (i.e., B-ALL enriched DAS) also exhibit AP-1

TF occupancy (**Figure 3F**), thereby supporting AP-1-associated *cis*-regulatory rewiring in B-ALL. We

determined that even though most AP-1 occupied B-ALL enriched DAS localized to promoter-distal
 regions of the human genome (77%), there is a 2.7-fold enrichment for AP-1 occupancy at B-ALL

enriched promoters compared to B-ALL enriched DAS devoid of AP-1 occupancy (Figure 3G; 16% vs
6%). Further integration of AP-1 occupied B-ALL enriched DAS with promoter capture Hi-C in B-ALL
cell lines identified target genes that were enriched for cell cycle, autophagy and apoptotic signaling
pathways (Table S6; example in Figure 3H).

211 As an extension of our TF footprinting data we also integrated B-ALL cell line promoter capture 212 Hi-C using the ABC enhancer algorithm to refine identification of TF-target gene relationships across 213 top TFs and a cancer implicated gene set <sup>26</sup>. Specifically, we focused on top TF footprints within B-ALL 214 enriched DAS and the cancer implicated gene targets of these DAS predicted by the ABC enhancer 215 algorithm. Concordant with global TF footprint and AP-1 TF occupancy analyses we identified the AP-1 216 family as top TFs in this network. We also identified other top TFs from TF footprinting such as CEBP 217 family TFs and BACH2 (Figure 3I). Other prominent top TFs include NFIC, XBP1, TBX1 and numerous 218 basic helix-loop-helix (bHLH) class TFs (e.g., MYOG, MYF5 and HES5). Top expressed cancer implicated gene targets for each TF converged on notable genes involved in cell signaling (TGFBR2, 219 220 CXCR4), histone mark modification (ARID5B), transcriptional regulation (MYC, KLF6, HIF1A) and the 221 PI3K-AKT pathway (*PTEN*) (Figure 3I). Collectively, these results highlight a rewiring of signaling 222 pathways and TF binding networks that facilitate the proliferative potential of B-ALL samples compared 223 to Pro-B cells.

224

#### 225 Identification of subtype-enriched chromatin architecture

226 To better understand chromatin accessibility within B-ALL, inter-subtype analyses were performed to 227 identify DAS exhibiting subtype-enriched signal (i.e., henceforth referred to as subtype-enriched DAS) 228 in 10 B-ALL molecular subtypes harboring known molecular drivers (BCR::ABL1, DUX4-rearranged, 229 ETV6::RUNX1, high hyperdiploid, low hypodiploid, KMT2A-rearranged, Ph-like, PAX5-altered, 230 TCF3::PBX1 and ZNF384-rearranged; Figures 4A and 4C). For this analysis, we compared a single B-231 ALL subtype cohort with all other B-ALL cell samples not belonging to that subtype in pairwise fashion 232 covering all subtypes. This approach was utilized to emphasize high degrees of subtype enrichment 233 compared to the full spectrum of chromatin accessibility variability in the remaining sample cohort. We 234 identified between 307 and 10.639 DAS in each B-ALL subtype, with a total of 42,457 subtype-enriched 235 DAS identified across all 10 B-ALL subtypes (log<sub>2</sub> fold change > or < 1, FDR<0.05; Figure 4B, Table 236 **S7**). We annotated subtype-enriched DAS on a subtype basis and determined that a majority of 237 subtype-enriched DAS in each B-ALL subtype (87%, range=80%-90%) localized to promoter-distal 238 regions of the genome (intronic and distal intergenic; Figure 4D), and 43%, on average (range=39%-239 49%), localized to distal intergenic regions, thereby emphasizing the importance of non-genic loci in 240 defining B-ALL chromatin heterogeneity.

241 To further evaluate subtype-enriched DAS, we determined if they displayed enrichment patterns 242 that were consistent with five established human B-ALL cell lines (697= TCF3::PBX1, Nalm6= DUX4-243 rearranged, REH= ETV6::RUNX1, SEM= KMT2A-rearranged and SUPB15= BCR::ABL1). Concordant 244 with DAS in patient samples, subtype-enriched DAS exhibited the strongest (BCR-ABL, DUX4-245 rearranged, ETV6::RUNX1, KMT2A-rearranged) or second strongest (TCF3::PBX1) accessibility in the 246 concordant cell line that was representative of that subtype (Figure S3). These data suggest that B-247 ALL cell lines exhibit chromatin accessibility that is largely consistent with primary B-ALL cell sample 248 from the corresponding subtype.

- 249 To further determine functional effects on gene expression, we integrated subtype-enriched 250 DAS with DEGs uniquely up-regulated (log<sub>2</sub> fold change >1, FDR<0.05) in each of the 10 B-ALL 251 molecular subtypes to determine if they were enriched near DEGs. We identified a statistically 252 significant enrichment of subtype-enriched DAS near up-regulated DEGs in 9 of 10 subtypes compared 253 to total expressed genes in the corresponding subtype (Kolmogorov-Smirnov test p< 0.05; Figure 4E. 254 Figure S4) and uncovered a strong statistical trend in Ph-like B-ALL (Kolmogorov-Smirnov test p= 255 0.06; Figure S4). Consequently, these data support the role of subtype-enriched DAS in gene 256 regulation and gene activation and further suggest that differences in chromatin accessibility contribute 257 to transcriptomic differences among B-ALL subtypes <sup>3,4</sup>. Collectively, these results highlight extensive 258 open chromatin heterogeneity among B-ALL molecular subtypes.
- 259

#### 260 Mapping transcription factor drivers and gene regulatory networks in B-ALL subtypes

261 We performed TF footprint profiling using merged ATAC-seg signal from 10 B-ALL subtypes with 262 known molecular drivers to identify subtype-enriched TF drivers. TF footprint profiling <sup>12</sup> identified 263 between 4,303,155 and 5,441,937 bound motifs in each B-ALL subtype, with 49,402,067 TF footprints 264 at 815,992 unique genomic loci identified across all subtypes. Using these data, we next identified key 265 TF footprints that were enriched in each subtype (i.e., subtype-enriched TF footprints) by calculating 266 differential footprint scores between every subtype-subtype pair for each TF motif. The top median 267 differential motif scores for each subtype were selected as subtype-enriched TF footprints. This 268 approach was utilized to emphasize differential TF footprint motifs that were consistent and distinct for 269 each subtype rather than repetitive global trends (Figure 5A). Notably, subtype-enriched TF footprints 270 were identified for recognized TF drivers such as DUX4 in DUX4-rearranged ALL and ZNF384 in 271 ZNF384-rearranged ALL. We also identified HOX family TFs (HOXA9, HOXB9, HOXC9 and HOXD9) in 272 KMT2A-rearranged ALL, GATA family TFs (GATA2, GATA3, GATA4, GATA5 and GATA6) in ZNF384-273 rearranged ALL and nuclear receptor family TFs in PAX5-altered ALL (ESR1, ESR2, ESRRA, NR2F6, 274 NR2F1, RARA and THRB) that all had strong subtype-enriched TF footprints.

Because DNA consensus motifs can be highly redundant within TF families, we integrated subtype-enriched TF footprints with DEGs uniquely up-regulated in each subtype to identify candidate TFs from these TF families that are up-regulated in the corresponding B-ALL subtype. This analysis identified *HOXA9* and *HOXC9*, *RARA* and *GATA3* as up-regulated genes in *KMT2A*-rearranged, *PAX5*altered and *ZNF384*-rearranged subtypes, respectively (**Figure 5B**, **Figure S5**). In addition, *DUX4* (*DUX4*-rearranged) and *MEIS1* (*KMT2A*-rearranged) were also identified as up-regulated TF genes with subtype-enriched TF footprints (**Figure S5**).

- To determine if these up-regulated TFs promote unique chromatin accessibility landscapes among B-ALL subtypes, we also performed TF footprinting on subtype-enriched DAS by comparing differential footprint scores at subtype-enriched DAS between each B-ALL subtype and Pro-B cells (**Figure 5C**, **Figure S6**). Notably, these data supported a role of DUX4 in *DUX4*-rearranged ALL, ZNF384 and GATA3 in *ZNF384*-rearranged ALL, and HOXA9 and MEIS1 in *KMT2A*-rearranged ALL in
- the generation of subtype-specific chromatin landscapes (**Figure 5C**, **Figure S6**).
- 288

#### 289 Predictive potential of B-ALL subtype-enriched DAS

290 We determined how well chromatin accessibility can predict B-ALL subtypes by constructing a stepwise 291 Principal Component Analysis-Linear Discriminant Analysis (PCA-LDA) classification model using the 292 42,457 subtype-enriched DAS ATAC-seq read count matrix as initial input across 10 B-ALL subtypes 293 harboring known molecular drivers (outlined in **Figure 6A**). Notably, the constructed classification 294 model was tested with leave-one-out cross validation at an accuracy of 86%. The most common failure 295 was incorrect classification of BCR::ABL1 and Ph-like subtypes (Figure 6B), as has been observed 296 with other ALL classification algorithms <sup>27</sup>. Taking this into account by grouping *BCR::ABL1* and Ph-Like 297 subtype samples into a common class yielded a re-calculated cross validation accuracy of 91%. 298 Visualization of B-ALL subtype separations using select dimensions output by the LDA model 299 demonstrates distinct groupings of related subtypes emphasizing classification model performance 300 (Figure 6C).

As a further application of our classification model, we also applied the algorithm to 26 B-ALL patient samples of unknown molecular B-ALL subtype. Although transcriptomic profiling for B-ALL drivers is not available to fully validate these samples, when processed with the constructed PCA-LDA model and projected onto original LDA dimensions they distinctly cluster with known molecular subtypes supporting reasonable predictions (**Figure 6D**). Collectively, these data support the utility of chromatin structure and subtype-enriched DAS in B-ALL subtype classification.

- 307
- 308

#### 309 Mapping inherited DNA sequence variants that impact chromatin accessibility

310 To determine how germline variation impacts chromatin accessibility, we identified chromatin 311 accessibility quantitative trait loci using ATAC-seg (ATAC-QTLs) in a subset of 69 patient samples with 312 available SNP genotyping information and allele-specific ATAC-seg read counting using RASQUAL<sup>28</sup>. 313 In total, 9080 ATAC-QTLs were identified representing both directionalities, with reference or alternative 314 alleles increasing chromatin accessibility (FDR<0.1; Figure 7A, Table S8). Manual quantification and 315 scaling of allele-specific read counts for select ATAC-QTLs identified with RASQUAL demonstrated a 316 clear concordance and directionality among individual patient samples classified into genotype groups 317 (Figure 7B). Visual inspection of merged read counts from patient samples grouped into reference 318 allele homozygote, heterozygote, or alternate allele homozygote for select ATAC-QTLs further supports 319 the high-quality nature of identified ATAC-QTLs (Figure 7C). We further determined that 218 ATAC-QTLs where also lead eQTL SNPs when compared to GTEx eQTLs <sup>29</sup> from relevant tissues (blood and 320 321 lymphoblastoid cells), with 85% also concordant for allele overrepresentation directionality (Figure 7D; 322 Table S9). ATAC-QTLs were also compared with inherited genome-wide association study (GWAS) variants for ALL disease susceptibility which identified rs3824662 (GATA3)<sup>30</sup> and rs17481869 (2p22.3) 323 <sup>31</sup> as ATAC-QTLs that were associated with risk of developing B-ALL. Further supporting the validity of 324 325 our methodology, rs3824662 was also identified as an ATAC-QTL in ALL PDX samples <sup>32</sup>, and we 326 functionally validated differential allele-specific activity for rs17481869 in multiple B-ALL cell lines 327 (Figure S7).

328 To infer the impact of TF binding in control of chromatin accessibility at ATAC-QTLs we 329 overlapped ATAC-QTL loci with TF motifs determined as TF-bound by footprint profiling <sup>12</sup>. Nearly one-330 third (28.8%; 2615/9080 ATAC-QTLs) of these ATAC-QTLs overlapped a TF-bound motif footprint 331 across multiple B-ALL subtypes, suggesting that most ATAC-QTLs do not have a clear TF-binding 332 mechanism in how they impact chromatin accessibility. Analysis of bound TF motif footprint prevalence 333 at ATAC-QTLs identified several ETS family TFs (EHF, ELF3, SPI1/PU.1 and SPIB), zinc finger TFs 334 (ZNF263, ZNF460, ZNF740 and ZNF148) and CTCF as the most altered motifs leading to differences 335 in chromatin accessibility between alleles (Figure 7E). Notably, we also identified PAX5 and IKZF1, which have known roles in B-cell development and leukemogenesis <sup>33-36</sup>. Collectively, these data 336 337 identify inherited DNA sequence variants contributing to chromatin heterogeneity among B-ALL 338 subtypes and indicate specific TFs of interest for further exploration of ATAC-QTLs.

- 339
- 340
- 341
- 342

#### 343 **DISCUSSION**

344 Our study provides the first, large-scale examination of chromatin accessibility in the B-ALL genome 345 across an expansive set of B-ALL subtypes. We further integrated this data with ChIP-seg histone 346 modification enrichment in primary B-ALL cells and three-dimensional chromatin looping data using 347 promoter capture Hi-C in multiple B-ALL cell lines. Our data demonstrate that most regions of 348 chromatin accessibility harbor activating chromatin marks consistent with *cis*-regulatory elements 349 involved in gene regulation, and we further confirmed direct looping to gene promoters for 350 approximately 50% of accessible chromatin sites. However, this does not rule out more transient chromatin looping interactions difficult to detect by current chromatin conformation capture genomic 351 352 techniques.

353 Extensive epigenomic reprogramming was uncovered between B-cell progenitors and B-ALL, 354 and cell-of-origin analyses identified Pro-B cells as the most common cell-of-origin. Our comparison of 355 B-ALL and pro-B cell chromatin accessibility suggests epigenomic reprogramming that is, in part, 356 associated with AP-1 TF occupancy. We further identify disruptions to normal B-cell function through 357 the activation of toll-like receptor signaling and interleukin production. Acetyl Co-A synthesis was also 358 identified as an enriched gene ontology term when comparing B-ALL and Pro-B cells. Metabolic 359 alterations in cancer are well known, particularly acetyl-Co-A synthesis alterations which have been previously reported in cancer <sup>37</sup>. In addition to metabolic alterations, *PTEN*, a known tumor suppressor 360 gene is frequently mutated in a large portion of cancers <sup>38</sup>. However, in B-ALL the cancer role of PTEN 361 has been reported to be inverted, functioning instead as an oncogene <sup>39</sup>. Reinforcing this conclusion 362 363 and further suggesting PTEN as an intriguing target for B-ALL treatment, we also found PTEN in our 364 network as a top gene target of B-ALL enriched DAS.

365 We further examined accessible chromatin landscapes among diverse molecular subtypes of B-366 ALL. Collectively, we identified 42,457 subtype-enriched DAS which strikingly represent 20% of 367 analyzed accessible chromatin sites across a pan-subtype B-ALL genome. Subtype-enriched DAS 368 were enriched near up-regulated DEG in the corresponding subtype, supporting their role in gene 369 activation. Moreover, comparisons between subtype-enriched DAS and chromatin accessibility data 370 from cell lines identified largely consistent patterns. We further identified candidate TFs that exhibited 371 strong subtype-specificity through TF footprinting analyses and validated some of these findings using transcriptomic data from primary B-ALL cells. Collectively, these analyses highlighted the role of 372 373 HOXA9 and MEIS1 in KMT2A-rearranged ALL, GATA3 in ZNF384-rearranged ALL and RARA in 374 PAX5-altered B-ALL. We further confirmed the previously reported roles of DUX4 and ZNF384 in 375 DUX4-rearranged and ZNF384-rearranged ALLs, respectively. Concordant with our findings, previous 376 studies have identified the co-upregulation of HOXA9 and MEIS1 in KMT2A-rearranged leukemias and

further support that these TFs are key drivers of leukemogenesis <sup>40-42</sup>. Our identification of numerous 377 378 HOX TFs with enriched footprints in *KMT2A*-rearranged ALL is also consistent with observations of HOX gene dysregulation in this subtype <sup>43</sup>. Further supporting our results, ZNF384 fusion proteins in 379 ZNF384-rearranged ALL are known to up-regulate GATA3 expression <sup>44,45</sup>. Although a direct role for 380 381 RARA in PAX5-altered B-ALL has not been established, previous work has identified PAX5 as a target 382 gene of the PLZF-RARA fusion protein in acute promyelocytic leukemia <sup>46</sup>. Moreover, both *RARA* and 383 PAX5 genes can form fusions with PML in acute promyelocytic leukemia <sup>47</sup> and ALL <sup>48</sup>, respectively. 384 While PAX5-altered ALL has not been well connected to RARA nuclear receptor signaling, there has 385 been previous work treating IKZF1 mutated BCR-ABL1 ALL with RARA and RXR agonists that suppressed a self-renewal phenotype <sup>49</sup>. Collectively, these data warrant further investigation of RARA 386 387 and RXR signaling in PAX5-altered ALL.

388 Supporting the utility of chromatin accessibility in B-ALL classification, subtype-enriched DAS 389 predicted subtypes with 86% accuracy. As a comparison to chromatin accessibility, transcriptional 390 profiling using ALLSorts correctly assigned B-ALL subtypes with 92% accuracy <sup>27</sup>. However, this RNA-391 seq dataset included over 1223 transcriptomes from 18 subtypes representing a considerably larger 392 dataset for model development. We therefore suspect that additional chromatin accessibility profiling 393 across more B-ALL subtypes and increased sample sizes will lead to even better subtype prediction 394 that will rival transcriptomic profiling and importantly, incorporate intergenic heterogeneity that can 395 elucidate *cis*-regulatory drivers of B-ALL leukemogenesis.

To identify the role of inherited DNA sequence variation on the B-ALL chromatin landscape, we mapped over 9000 ATAC-QTLs (FDR<0.1). A large subset of ATAC-QTLs mapped to TF footprints and were concordant in allelic biases with GTEx lead eQTLs. Further validating our analysis, we functionally validated a variant (rs17481869; 2p22.3) associated with susceptibility to ALL <sup>31</sup>. Collectively, this analysis suggests that chromatin accessibility is additionally modified by inherited DNA sequence variation, thereby further contributing to increased chromatin heterogeneity in B-ALL.

Overall, our data support pronounced changes in chromatin accessibility between B-ALL and precursor B-cells, as well as among B-ALL subtypes. Our results further support the role of diverse TFs and inherited genetic variants in modulating and promoting differences in chromatin accessibility among B-ALL subtypes. Ultimately, these diverse chromatin architectures contribute to unique gene regulatory networks and transcriptional programs. Our work therefore provides a valuable resource to the cancer genomics research community and can be further used to better understand biological as well as clinical differences among B-ALL subtypes.

409

410

## 411 METHODS

#### 412 Patient samples

413 Patient samples were obtained from: St. Jude Children's Research Hospital (Memphis, Tennessee),

- 414 ECOG-ACRIN Cancer Research Group, The Alliance for Clinical Trials in Oncology, MD Anderson
- 415 Cancer Center (Houston, Texas), Cook Children's Medical Center (Fort Worth, Texas), Lucile Packard
- 416 Children's Hospital (Palo Alto, California), The University of Chicago (Chicago, Illinois), Novant Health
- 417 Hemby Children's Hospital (Charlotte, North Carolina) and Children's Hospital of Michigan (Detroit,
- 418 Michigan). All patients or their legal guardians provided written informed consent. The use of these
- samples was approved by the institutional review board at St. Jude Children's Research Hospital.
- 420

#### 421 Functional genomic studies

- ATAC-seq using the Fast-ATAC<sup>10</sup> protocol was performed on 10,000 fresh primary ALL cells. H3K27ac
  ChIP-seq was performed as previously described<sup>50</sup> on 20 million fresh primary ALL cells. CUT&RUN for
  FOSL2/Fra2 (Cell signaling; 19967S), JUN (Epicypher; 13-2019) and JUNB (Cell Signaling; 3753S)
  was performed using the Epicypher Cutana CUT&RUN kit v3.0 (14-1048) according to the
  manufacturers provided instructions. Next-generation sequencing of ATAC-seq, CUT&RUN, and ChIP-
- 427 seq was performed at the Hartwell Center for Bioinformatics and Biotechnology at St. Jude Children's
- 428 Research Hospital. Transcriptomic and SNP genotyping data from B-ALL patient samples were
- 429 obtained from St. Jude Children's Research Hospital. Normal B-cell ATAC-seq <sup>10,25</sup> were downloaded
- 430 from NCBI (GSE122989 and GSE74912). B-ALL cell histone modification ChIP-seq datasets
- 431 (H3K27ac, H3K4me1 and H3K27me3) were downloaded from the Blueprint Epigenome Consortium
- 432 (https://www.blueprint-epigenome.eu/). Expression quantitative trait loci (eQTL) data was obtained from
- 433 previous studies <sup>51</sup>. Arima promoter capture Hi-C (Arima; A510008, A303010, A302010) was performed
- 434 on 10 million B-ALL cell lines (697, BALL1, Nalm6, RS411, REH, SEM and SUPB15) according to the
- 435 manufacturers provided instructions using unspecified proprietary buffers, solutions, enzymes, and
- 436 reagents. See **Supplemental Methods** for additional details.
- 437

#### 438 Data analysis

- ATAC-seq and ChIP-seq reads were mapped to the hg19 reference genome using bowtie2 <sup>52</sup> and
   peaks were identified using MACS2 <sup>53</sup>. Regions of interest for ATAC-seq analyses were selected using
- 441 a reproducible peak summit approach within each subtype cohort with subsequent region merging.
- 442 DESeq2<sup>54</sup> was employed to identify B-ALL-enriched or subtype-enriched differentially accessible
- 443 chromatin sites (DAS). Two B-ALL subtype patient samples (IKZF1 N159Y and iAMP21) were included
- in B-ALL versus Pro-B cell analyses but were excluded from additional studies due to limited sample

445 size. Promoter capture Hi-C libraries from B-ALL cell lines were analyzed at 3-kb resolution using the 446 Arima CHiC pipeline (v1.4, https://github.com/ArimaGenomics/CHiC). Genomic regions representing 447 separate loop ends were compiled to facilitate overlap determinations with B-ALL patient chromatin 448 accessible regions of interest using "bedtools intersect". Enhancer and target gene prediction for 449 network construction was analyzed with the ABC enhancer algorithm 450 (https://github.com/broadinstitute/ABC-Enhancer-Gene-Prediction). In brief, inputs for the ABC 451 enhancer algorithm included, B-ALL enriched DAS, merged B-ALL patient ATAC-seg, H3K27Ac ChIP-452 seq. Arima promoter capture Hi-C contact counts with ABC score threshold at 0.04. The Genomic Regions Enrichment of Annotations Tool (GREAT)<sup>55</sup> was used to identify candidate target gene sets 453 and ontologies associated with DAS. TOBIAS <sup>12</sup> was used to identify TF footprints at accessible 454 chromatin sites. The Principal Component Analysis-Linear Discriminant Analysis (PCA-LDA) subtype 455 456 classification model was constructed stepwise by first PCA transformation of subtype-enriched ATACseq counts, then applying LDA on an optimized number of principal components. RASQUAL <sup>28</sup> was 457 458 used to map chromatin accessibility quantitative trait loci using ATAC-seq (ATAC-QTLs). Significant 459 ATAC-QTLs for each region were identified with a genome-wide computed FDR of 10%. See 460 Supplemental Methods for additional details.

- 461
- 462
- 463

# 464 DATA AND CODE AVAILABILITY

Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Daniel Savic (daniel.savic@stjude.org).

467

## 468 **ACKNOWLEDGEMENTS**

We would like to thank the Hartwell Center at St. Jude for ATAC-seq, ChIP-seq and promoter capture
Hi-C library preparation and next-generation sequencing. We would also like to thank Jeremy Hunt and
Brandon Smart for technical support. This work was supported by the National Cancer Institute
(R01CA234490, P30CA021765, UG1CA232760, UG1CA189859, and U10CA180820), the National
Institute of General Medical Studies (P50GM115279) and the American Lebanese Syrian Associated
Charities (ALSAC). The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.

476

# 477 **DECLARATIONS OF INTEREST**

- 478 The authors declare no competing interests.
- 479

# 480 **AUTHOR CONTRIBUTIONS**

- 481 Conceptualization, K.R. Barnett, D.S.; Methodology, K.R. Barnett, D.S.; Investigation, K.R. Barnett,
- 482 J.D.D., B.P.B, K.R. Bhattarai; Analysis, K.R. Barnett, D.S.; Data Curation, K.R.B., W.Y.; Patient sample
- 483 acquisition, K.R.C., C.S.M., E.J., E.P., M.R.L., S.M.K., W.S., H.I., S.J., C.H.P., C.G.M., M.V.R., W.E.E.,
- 484 J.J.Y.; Writing Original Draft, K.R. Barnett, D.S.; Writing Review & Editing, K.R. Barnett, J.D.D.,
- 485 B.P.B, K.R. Bhattarai, W.Y., K.R.C., C.S.M., E.J., E.P., M.R.L., S.M.K., W.S., H.I., S.J., C.H.P., C.G.M.,
- 486 M.V.R., W.E.E., J.J.Y, D.S.
- 487

## 488 **REFERENCES**

- Moriyama, T., Relling, M.V., and Yang, J.J. (2015). Inherited genetic variation in childhood acute
   lymphoblastic leukemia. Blood *125*, 3988-3995. 10.1182/blood-2014-12-580001.
- 491 2. Mullighan, C.G. (2012). Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin
  492 Invest *122*, 3407-3415. 10.1172/JCI61203.
- Lilljebjorn, H., Henningsson, R., Hyrenius-Wittsten, A., Olsson, L., Orsmark-Pietras, C., von
   Palffy, S., Askmyr, M., Rissler, M., Schrappe, M., Cario, G., et al. (2016). Identification of ETV6 RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic
   leukaemia. Nat Commun 7, 11790. 10.1038/ncomms11790.
- 4. Andersson, A., Olofsson, T., Lindgren, D., Nilsson, B., Ritz, C., Eden, P., Lassen, C., Rade, J.,
  498 Fontes, M., Morse, H., et al. (2005). Molecular signatures in childhood acute leukemia and their
  499 correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci
  500 U S A *102*, 19069-19074. 10.1073/pnas.0506637102.
- Figueroa, M.E., Chen, S.C., Andersson, A.K., Phillips, L.A., Li, Y., Sotzen, J., Kundu, M.,
   Downing, J.R., Melnick, A., and Mullighan, C.G. (2013). Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest *123*, 3099-3111.
   10.1172/JCI66203.
- Almamun, M., Levinson, B.T., van Swaay, A.C., Johnson, N.T., McKay, S.D., Arthur, G.L.,
   Davis, J.W., and Taylor, K.H. (2015). Integrated methylome and transcriptome analysis reveals
   novel regulatory elements in pediatric acute lymphoblastic leukemia. Epigenetics *10*, 882-890.
   10.1080/15592294.2015.1078050.
- 5097.Klemm, S.L., Shipony, Z., and Greenleaf, W.J. (2019). Chromatin accessibility and the510regulatory epigenome. Nat Rev Genet 20, 207-220. 10.1038/s41576-018-0089-8.
- Bhagwat, A.S., Lu, B., and Vakoc, C.R. (2018). Enhancer dysfunction in leukemia. Blood *131*, 1795-1804. 10.1182/blood-2017-11-737379.
- Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y., and Greenleaf, W.J. (2013).
   Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin,
   DNA-binding proteins and nucleosome position. Nat Methods *10*, 1213-1218.
   10.1038/nmeth.2688.
- 10. Corces, M.R., Buenrostro, J.D., Wu, B., Greenside, P.G., Chan, S.M., Koenig, J.L., Snyder,
  518 M.P., Pritchard, J.K., Kundaje, A., Greenleaf, W.J., et al. (2016). Lineage-specific and single-cell
  519 chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat Genet *48*,
  520 1193-1203. 10.1038/ng.3646.

- Boyle, A.P., Davis, S., Shulha, H.P., Meltzer, P., Margulies, E.H., Weng, Z., Furey, T.S., and
  Crawford, G.E. (2008). High-resolution mapping and characterization of open chromatin across
  the genome. Cell *132*, 311-322. 10.1016/j.cell.2007.12.014.
- Bentsen, M., Goymann, P., Schultheis, H., Klee, K., Petrova, A., Wiegandt, R., Fust, A.,
  Preussner, J., Kuenne, C., Braun, T., et al. (2020). ATAC-seq footprinting unravels kinetics of
  transcription factor binding during zygotic genome activation. Nat Commun *11*, 4267.
  10.1038/s41467-020-18035-1.
- 528 13. Gusmao, E.G., Allhoff, M., Zenke, M., and Costa, I.G. (2016). Analysis of computational
  529 footprinting methods for DNase sequencing experiments. Nat Methods *13*, 303-309.
  530 10.1038/nmeth.3772.
- 531 14. Zhang, K., Hocker, J.D., Miller, M., Hou, X., Chiou, J., Poirion, O.B., Qiu, Y., Li, Y.E., Gaulton,
  532 K.J., Wang, A., et al. (2021). A single-cell atlas of chromatin accessibility in the human genome.
  533 Cell *184*, 5985-6001 e5919. 10.1016/j.cell.2021.10.024.
- 15. Corces, M.R., Granja, J.M., Shams, S., Louie, B.H., Seoane, J.A., Zhou, W., Silva, T.C.,
  535 Groeneveld, C., Wong, C.K., Cho, S.W., et al. (2018). The chromatin accessibility landscape of
  536 primary human cancers. Science *362*. 10.1126/science.aav1898.
- 16. Cejas, P., Xie, Y., Font-Tello, A., Lim, K., Syamala, S., Qiu, X., Tewari, A.K., Shah, N., Nguyen,
  538 H.M., Patel, R.A., et al. (2021). Subtype heterogeneity and epigenetic convergence in
  539 neuroendocrine prostate cancer. Nat Commun *12*, 5775. 10.1038/s41467-021-26042-z.
- Roadmap Epigenomics, C., Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., HeraviMoussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015). Integrative analysis of 111
  reference human epigenomes. Nature *518*, 317-330. 10.1038/nature14248.
- 543 18. Creyghton, M.P., Cheng, A.W., Welstead, G.G., Kooistra, T., Carey, B.W., Steine, E.J., Hanna,
  544 J., Lodato, M.A., Frampton, G.M., Sharp, P.A., et al. (2010). Histone H3K27ac separates active
  545 from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A *107*, 21931546 21936. 10.1073/pnas.1016071107.
- Heintzman, N.D., Stuart, R.K., Hon, G., Fu, Y., Ching, C.W., Hawkins, R.D., Barrera, L.O., Van
  Calcar, S., Qu, C., Ching, K.A., et al. (2007). Distinct and predictive chromatin signatures of
  transcriptional promoters and enhancers in the human genome. Nat Genet *39*, 311-318.
  10.1038/ng1966.
- Hoffman, B.G., Robertson, G., Zavaglia, B., Beach, M., Cullum, R., Lee, S., Soukhatcheva, G.,
  Li, L., Wederell, E.D., Thiessen, N., et al. (2010). Locus co-occupancy, nucleosome positioning,
  and H3K4me1 regulate the functionality of FOXA2-, HNF4A-, and PDX1-bound loci in islets and
  liver. Genome Res 20, 1037-1051. 10.1101/gr.104356.109.
- Mifsud, B., Tavares-Cadete, F., Young, A.N., Sugar, R., Schoenfelder, S., Ferreira, L., Wingett,
  S.W., Andrews, S., Grey, W., Ewels, P.A., et al. (2015). Mapping long-range promoter contacts
  in human cells with high-resolution capture Hi-C. Nat Genet *47*, 598-606. 10.1038/ng.3286.
- Sondka, Z., Bamford, S., Cole, C.G., Ward, S.A., Dunham, I., and Forbes, S.A. (2018). The
  COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat
  Rev Cancer *18*, 696-705. 10.1038/s41568-018-0060-1.
- 561 23. Consortium, I.T.P.-C.A.o.W.G. (2020). Pan-cancer analysis of whole genomes. Nature 578, 82-562 93. 10.1038/s41586-020-1969-6.
- Jackson, T.R., Ling, R.E., and Roy, A. (2021). The Origin of B-cells: Human Fetal B Cell
  Development and Implications for the Pathogenesis of Childhood Acute Lymphoblastic
  Leukemia. Front Immunol *12*, 637975. 10.3389/fimmu.2021.637975.
- 566 25. O'Byrne, S., Elliott, N., Rice, S., Buck, G., Fordham, N., Garnett, C., Godfrey, L., Crump, N.T.,
  567 Wright, G., Inglott, S., et al. (2019). Discovery of a CD10-negative B-progenitor in human fetal
  568 life identifies unique ontogeny-related developmental programs. Blood *134*, 1059-1071.
  569 10.1182/blood.2019001289.
- 570 26. Fulco, C.P., Nasser, J., Jones, T.R., Munson, G., Bergman, D.T., Subramanian, V., Grossman,
  571 S.R., Anyoha, R., Doughty, B.R., Patwardhan, T.A., et al. (2019). Activity-by-contact model of

572 enhancer-promoter regulation from thousands of CRISPR perturbations. Nat Genet *51*, 1664-573 1669. 10.1038/s41588-019-0538-0.

- Schmidt, B., Brown, L.M., Ryland, G.L., Lonsdale, A., Kosasih, H.J., Ludlow, L.E., Majewski,
  I.J., Blombery, P., Ekert, P.G., Davidson, N.M., and Oshlack, A. (2022). ALLSorts: an RNA-Seq
  subtype classifier for B-cell acute lymphoblastic leukemia. Blood Adv *6*, 4093-4097.
  10.1182/bloodadvances.2021005894.
- 578 28. Kumasaka, N., Knights, A.J., and Gaffney, D.J. (2016). Fine-mapping cellular QTLs with 579 RASQUAL and ATAC-seq. Nat Genet *48*, 206-213. 10.1038/ng.3467.
- S80 29. Consortium, G.T., Laboratory, D.A., Coordinating Center -Analysis Working, G., Statistical
  S81 Methods groups-Analysis Working, G., Enhancing, G.g., Fund, N.I.H.C., Nih/Nci, Nih/Nhgri,
  S82 Nih/Nimh, Nih/Nida, et al. (2017). Genetic effects on gene expression across human tissues.
  S83 Nature 550, 204-213. 10.1038/nature24277.
- S84 30. Perez-Andreu, V., Roberts, K.G., Harvey, R.C., Yang, W., Cheng, C., Pei, D., Xu, H., GastierFoster, J., E, S., Lim, J.Y., et al. (2013). Inherited GATA3 variants are associated with Ph-like
  childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet *45*, 1494-1498.
  10.1038/ng.2803.
- Vijayakrishnan, J., Studd, J., Broderick, P., Kinnersley, B., Holroyd, A., Law, P.J., Kumar, R.,
  Allan, J.M., Harrison, C.J., Moorman, A.V., et al. (2018). Genome-wide association study
  identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nat Commun 9,
  1340. 10.1038/s41467-018-03178-z.
- S2. Yang, H., Zhang, H., Luan, Y., Liu, T., Yang, W., Roberts, K.G., Qian, M.X., Zhang, B., Yang,
  W., Perez-Andreu, V., et al. (2022). Noncoding genetic variation in GATA3 increases acute
  lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nat
  Genet *54*, 170-179. 10.1038/s41588-021-00993-x.
- 59633.Medvedovic, J., Ebert, A., Tagoh, H., and Busslinger, M. (2011). Pax5: a master regulator of B597cell development and leukemogenesis. Adv Immunol *111*, 179-206. 10.1016/B978-0-12-598385991-4.00005-2.
- 59934.Gu, Z., Churchman, M.L., Roberts, K.G., Moore, I., Zhou, X., Nakitandwe, J., Hagiwara, K.,600Pelletier, S., Gingras, S., Berns, H., et al. (2019). PAX5-driven subtypes of B-progenitor acute601lymphoblastic leukemia. Nat Genet *51*, 296-307. 10.1038/s41588-018-0315-5.
- Mullighan, C.G., Su, X., Zhang, J., Radtke, I., Phillips, L.A., Miller, C.B., Ma, J., Liu, W., Cheng,
  C., Schulman, B.A., et al. (2009). Deletion of IKZF1 and prognosis in acute lymphoblastic
  leukemia. N Engl J Med *360*, 470-480. 10.1056/NEJMoa0808253.
- 605 36. Churchman, M.L., Qian, M., Te Kronnie, G., Zhang, R., Yang, W., Zhang, H., Lana, T., Tedrick,
  606 P., Baskin, R., Verbist, K., et al. (2018). Germline Genetic IKZF1 Variation and Predisposition to
  607 Childhood Acute Lymphoblastic Leukemia. Cancer Cell *33*, 937-948 e938.
  608 10.1016/j.ccell.2018.03.021.
- Guertin, D.A., and Wellen, K.E. (2023). Acetyl-CoA metabolism in cancer. Nat Rev Cancer.
   10.1038/s41568-022-00543-5.
- Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and
  Stratton, M.R. (2004). A census of human cancer genes. Nat Rev Cancer *4*, 177-183.
  10.1038/nrc1299.
- Shojaee, S., Chan, L.N., Buchner, M., Cazzaniga, V., Cosgun, K.N., Geng, H., Qiu, Y.H., von
  Minden, M.D., Ernst, T., Hochhaus, A., et al. (2016). PTEN opposes negative selection and
  enables oncogenic transformation of pre-B cells. Nat Med *22*, 379-387. 10.1038/nm.4062.
- Collins, C., Wang, J., Miao, H., Bronstein, J., Nawer, H., Xu, T., Figueroa, M., Muntean, A.G.,
  and Hess, J.L. (2014). C/EBPalpha is an essential collaborator in Hoxa9/Meis1-mediated
  leukemogenesis. Proc Natl Acad Sci U S A *111*, 9899-9904. 10.1073/pnas.1402238111.
- Sun, Y., Zhou, B., Mao, F., Xu, J., Miao, H., Zou, Z., Phuc Khoa, L.T., Jang, Y., Cai, S., Witkin,
  M., et al. (2018). HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.
  Cancer Cell *34*, 643-658 e645. 10.1016/j.ccell.2018.08.018.

- Miyamoto, R., Kanai, A., Okuda, H., Komata, Y., Takahashi, S., Matsui, H., Inaba, T., and
  Yokoyama, A. (2021). HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene
  expression for multiple anti-apoptotic pathways. Elife *10*. 10.7554/eLife.64148.
- Ferrando, A.A., Armstrong, S.A., Neuberg, D.S., Sallan, S.E., Silverman, L.B., Korsmeyer, S.J.,
  and Look, A.T. (2003). Gene expression signatures in MLL-rearranged T-lineage and Bprecursor acute leukemias: dominance of HOX dysregulation. Blood *102*, 262-268.
  10.1182/blood-2002-10-3221.
- 44. Qian, M., Zhang, H., Kham, S.K., Liu, S., Jiang, C., Zhao, X., Lu, Y., Goodings, C., Lin, T.N.,
  Kang, R., et al. (2017). Whole-transcriptome sequencing identifies a distinct subtype of acute
  Iymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
  Genome Res 27, 185-195. 10.1101/gr.209163.116.
- 45. Yaguchi, A., Ishibashi, T., Terada, K., Ueno-Yokohata, H., Saito, Y., Fujimura, J., Shimizu, T.,
  Ohki, K., Manabe, A., and Kiyokawa, N. (2017). EP300-ZNF384 fusion gene product upregulates GATA3 gene expression and induces hematopoietic stem cell gene expression
  signature in B-cell precursor acute lymphoblastic leukemia cells. Int J Hematol *106*, 269-281.
  10.1007/s12185-017-2220-6.
- 639 46. Spicuglia, S., Vincent-Fabert, C., Benoukraf, T., Tiberi, G., Saurin, A.J., Zacarias-Cabeza, J.,
  640 Grimwade, D., Mills, K., Calmels, B., Bertucci, F., et al. (2011). Characterisation of genome641 wide PLZF/RARA target genes. PLoS One 6, e24176. 10.1371/journal.pone.0024176.
- 642 47. Chen, Z., and Chen, S.J. (1992). RARA and PML genes in acute promyelocytic leukemia. Leuk 643 Lymphoma *8*, 253-260. 10.3109/10428199209051004.
- Kurahashi, S., Hayakawa, F., Miyata, Y., Yasuda, T., Minami, Y., Tsuzuki, S., Abe, A., and
  Naoe, T. (2011). PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.
  Oncogene *30*, 1822-1830. 10.1038/onc.2010.554.
- 647 49. Churchman, M.L., Low, J., Qu, C., Paietta, E.M., Kasper, L.H., Chang, Y., Payne-Turner, D.,
  648 Althoff, M.J., Song, G., Chen, S.C., et al. (2015). Efficacy of Retinoids in IKZF1-Mutated BCR649 ABL1 Acute Lymphoblastic Leukemia. Cancer Cell 28, 343-356. 10.1016/j.ccell.2015.07.016.
- Ferguson, D.C., McCorkle, J.R., Barnett, K.R., Bonten, E.J., Bergeron, B.P., Bhattarai, K.R.,
  Yang, W., Smith, C., Hansen, B.S., Bajpai, R., et al. (2022). Amino acid stress response genes
  promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Adv 6,
  3386-3397. 10.1182/bloodadvances.2022006965.
- Autry, R.J., Paugh, S.W., Carter, R., Shi, L., Liu, J., Ferguson, D.C., Lau, C.E., Bonten, E.J.,
  Yang, W., McCorkle, J.R., et al. (2020). Integrative genomic analyses reveal mechanisms of
  glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer *1*, 329-344.
  10.1038/s43018-020-0037-3.
- 65852.Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. Nat659Methods 9, 357-359. 10.1038/nmeth.1923.
- 53. Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C.,
  Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-based analysis of ChIP-Seq
  (MACS). Genome Biol 9, R137. 10.1186/gb-2008-9-9-r137.
- bove, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and
   dispersion for RNA-seq data with DESeq2. Genome Biol *15*, 550. 10.1186/s13059-014-0550-8.
- 66555.McLean, C.Y., Bristor, D., Hiller, M., Clarke, S.L., Schaar, B.T., Lowe, C.B., Wenger, A.M., and666Bejerano, G. (2010). GREAT improves functional interpretation of cis-regulatory regions. Nat667Biotechnol 28, 495-501. 10.1038/nbt.1630.
- 668
- 669
- 670

## 671 **FIGURE LEGENDS**

672

673 FIGURE 1: Chromatin accessibility landscapes in B-ALL. (A) Number and genomic location of 674 accessible chromatin sites for 10 B-ALL subtypes and B-other samples is provided. (B) Percentage of 675 B-ALL accessible chromatin sties that maps to H3K4me1 and/or H3K27ac active histone marks (Active; 676 green), H3K27me3 and H3K4me1 and/or H3K27ac bivalent or poised histone marks (Bivalent or 677 Poised; yellow) and H3K27me3 only repressed histone marks (Repressed; red). (C) B-ALL cell line 678 chromatin loops detected using promoter capture Hi-C at B-ALL accessible chromatin sites. The total 679 number of B-ALL accessible chromatin sites, number of B-ALL accessible chromatin sites within loops 680 and the total number of accessible chromatin sites with a loop to a gene implicated in cancer is shown. 681 (D) UCSC genome browser ATAC-seq signal track of average B-ALL chromatin accessibility and 682 promoter capture Hi-C loops across the IKZF1 gene locus. (E) UCSC genome browser ATAC-seq 683 signal tracks of 10 merged B-ALL subtypes with known molecular drivers across the *IKZF1* gene locus. 684 685 FIGURE 2: B-ALL cell type-of-origin defined by chromatin accessibility. (A) Differentiation timeline 686 of B-cell progenitors from least differentiated to most differentiated. HSC= hematopoietic stem cell, MPP= multipotent progenitor cell, LMPP= lymphoid-primed multipotent progenitor cell, CLP= common 687 688 lymphoid progenitor cell, PreProB= prePro-B cell, ProB= Pro-B cell and CD19+,CD20+= B cell. (B) 689 Heatmap of B-cell progenitor or B-ALL patient sample variance stabilized ATAC-seg signal across B-690 cell progenitor-defining chromatin loci. B-cell progenitor groups most similar to B-ALL patient samples 691 (preProB and ProB) are outlined in yellow. (C) Confusion matrix showing number (listed) and 692 percentage (color-coded) of B-cell progenitor truths and predictions for leave-one-out cross validation of 693 a K-nearest neighbor classifier model. (D) Distribution of B-cell progenitor classification across B-ALL 694 patient samples using a K-nearest neighbor classifier model trained with B-cell progenitor data.

695

696 FIGURE 3: Mapping differential accessibility between B-ALL and Pro-B cells. (A) Heatmap of Pro-697 B cell or B-ALL patient sample variance stabilized ATAC-seq signal as z-score across Pro-B cell and B-698 ALL enriched DAS. DAS within heatmap are > 1 or <  $-1 \log_2$ -adjusted fold change. (B) ATAC-seg signal 699 track examples of Pro-B-cell-enriched DAS and B-ALL-enriched DAS on the UCSC genome browser. Flanking genomic regions are included for context. (C) Gene ontology analysis of DAS with higher 700 701 accessibility in B-ALL (B-ALL-enriched) at various log<sub>2</sub>-adjusted fold change thresholds. All terms were 702 significant using both binomial and hypergeometric statistical tests. (D) Differential transcription factor 703 footprinting between Pro-B cells and B-ALL patient samples across 217,240 B-ALL genomic regions of 704 interest. (E) FOSL2 CUT&RUN enrichment heatmaps at all B-ALL accessible chromatin sites and B-

705 ALL enriched DAS (B-ALL enrich) in SUPB15 (left) and 697 (right) cells. (F) Number of B-ALL enriched 706 DAS overlapping AP-1 TF occupancy (FOSL2, JUN and/or JUNB) in 697 (left) SUPB15 (middle) and 707 both B-ALL cell lines (right). Number of overlapping sites are shown in purple while non-overlapping 708 sites are shown in yellow. (G) Genome annotation of B-ALL enriched DAS with AP-1 TF occupancy 709 (left) or that are devoid of AP-1 TF occupancy (right). (H) IGV genome browser image showing a B-ALL 710 enriched DAS that maps to accessible chromatin and sites of AP-1 TF occupancy in SUPB15 cells. 711 Promoter capture Hi-C (PC-HiC) looping between the distal AP-1 occupied sites and the IGFBP7 gene 712 promoter is shown. B-ALL (red) and pro-B (blue) cell ATAC-seg tracks are overlaid in the top panel. 713 Signal tracks for FOSL2, JUN and JUNB in SUBP15 cells are shown. (I) Transcription factor and target 714 gene network of DAS with higher accessibility in B-ALL (B-ALL-enriched). Network is subset for top 715 transcription factor footprints across DAS ranked by the top mean log<sub>2</sub>-adjusted fold change 716 transcription factor footprint signal. Target genes are subset for a cancer implicated gene set ranked by 717 the top expressed genes. Network connections are colored as transcription factors (purple blocks) to 718 target gene (green arrow heads) pairs. Select expansive and highly similar transcription factor motif 719 families are grouped (AP-1 and CEBP; AP1-family and CEBP-family).

720

721 FIGURE 4: Mapping differential accessibility among B-ALL molecular subtypes. (A) Heatmap of 722 variance stabilized ATAC-seg signal as z-score across subtype-enriched DAS. Enrichment patterns for 723 each subtype DAS set are shown on vertical axis and are grouped by B-ALL subtype patient sample on 724 the horizontal axis. Ph-like and BCR-ABL subtype-enriched DAS are expanded at the right for clarity. 725 (B) Pie chart shows the number and percentage of subtype-enriched DAS identified. (C) ATAC-seq 726 signal track examples of subtype-enriched DAS on the UCSC genome browser. (D) Genomic 727 annotations of subtype-enriched DAS for each B-ALL subtype is provided. The fraction of sites 728 harboring different annotations is plotted. (E) Cumulative distribution function for BCR::ABL1 and 729 ZNF384-rearranged ALL comparing the fraction (y-axis) of subtype up-regulated genes (Subtype 730 DEGs; gray or light green) and all expressed subtype genes (Expressed; black) at different distance 731 cutoffs from subtype-enriched DAS and their transcription start sites (x-axis). Kolmogorov-Smirnov (K-732 S) p-values are provided.

733

## 734 FIGURE 5: TF footprinting and gene regulatory networks identify key TF drivers in B-ALL

subtypes. (A) Heatmap list of the topmost consistently differential TF footprints between all pairwise
 subtype-subtype comparisons (y-axis; labeled to the right of the heatmap as TF motif identifiers)

737 enriched in 10 B-ALL subtypes (x-axis; labeled on top of heatmap as z-score of differential TF footprint

signal output by TOBIAS). (B) RNA-seq transcripts per million (TPM) expression of key TFs with

subtype-enriched footprints that are also up-regulated in the corresponding subtype (colored) versus all
other subtypes (gray). DESeq2 differentially expressed gene FDR significance values are provided. (C)
Top TF footprints at *KMT2A*-enriched DAS are shown. Differential footprint score between B-ALL and
Pro-B cells is provided on the x-axis and TF footprint significance is provided on the y-axis. Transcripts
per million (TPM) transcript abundance of associated TF transcript is shown as both color and size of

744


points.


745


FIGURE 6: Classification model accurately predicts B-ALL subtypes. (A) Flow chart outlines
process for PCA-LDA classification of B-ALL subtypes. (B) Confusion matrix showing number (listed)
and percentage (color-coded) of B-ALL subtype truths and predictions for leave-one-out cross
validation. (C) Three-dimensional plots showing clustering of B-ALL subtypes utilizing select
dimensions from the LDA model. (D) B-ALL subtype identification for unknown B-ALL samples (black
points). Clustering for unknown samples identified as *DUX4*-rearranged, *BCR::ABL1* and high
hyperdiploid (from left to right) is shown.


753

754 FIGURE 7: Identification of ATAC-QTLs impacting chromatin accessibility. (A) ATAC-QTL effect 755 size (x-axis) and significance (y-axis) is plotted for all significant ATAC-QTLs (FDR<0.1). (B) Examples 756 of allele-specific effects on ATAC-seq read count at ATAC-QTLs between samples from the three 757 genotype groups. Homozygous reference allele= homoz REF, heterozygous= heteroz REFALT and 758 homozygous alternative allele= homoz ALT. (C) UCSC browser ATAC-seq signal tracks of merged 759 BAM files from patients with distinct genotypes at ARL11 (top panel) and TTC7B (bottom panel) gene 760 loci. ATAC-QTLs are marked by an asterisk. Homozygous reference allele= homoz REF, 761 heterozygous= heteroz REFALT and homozygous alternative allele= homoz ALT. ENCODE ChIP-seq 762 TF binding sites are shown below each ATAC-seg signal track. (D) Scatterplot of effect size for SNPs 763 significant as both ATAC-QTLs (x-axis) and GTEx lead eQTL (y-axis). (E) Abundance of top TF-bound 764 motifs overlapping ATAC-QTLs. Highly similar TF motifs were grouped into motif families via TOBIAS 765 motif clustering as shown on the x-axis.













Figure 5



BCR-ABL

.

2

-2

Coord.2

-4

-6

0

2.5

-5.0

-2.5

0.0

Coord.2

-6

-5

0

5

10 15

Coord.1

20

